Saya Bio

Saya Bio has not publicly disclosed the names of its founders, managing partners, or investment committee members. The website and available materials describe the team only in collective terms. No named individuals appear in SEC filings or press releases as of mid-2026.

Saya states it sources through international partnerships — in-licensing biologic and biosimilar products from existing manufacturers and then funding the registration, marketing, and distribution efforts within Latin America. The firm does not disclose names of specific pharma partners or licensing terms.

Saya Bio is structured as an asset manager, not a family office. It deploys capital into early-stage pharmaceutical products rather than operating a traditional PE fund structure. The firm uses a hybrid model that includes fund-of-funds elements and direct product-level investments, though the exact legal structure has not been detailed publicly.

No. Saya does not run its own laboratories or discover new molecules. It targets drugs that are already developed and approved in major markets, funding their regulatory pathway and market entry in Latin American countries where biologic access remains limited.

Saya positions itself as a Pan-American biopharmaceutical company, with explicit focus on Latin America. The website discusses Latin American healthcare infrastructure and patient populations in the region, without naming individual countries where it operates.

No. As of mid-2026, Saya Bio has not named any portfolio companies, drug products, co-investors, or pharma partners in public materials. The pipeline is described in general terms — biologic and biosimilar therapies — without identifiable asset-level detail.

The source of Saya Bio's capital has not been disclosed. The firm describes itself as an asset manager and refers to a fund structure, but it does not identify limited partners, anchor investors, family office backing, or any other capital origin.